The Lobbying Register, read carefully Epicycle

Returns

Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.

Clear all

Showing returns filed by Pfizer .

Filed returns
57
match these filters
Matching filed returns per period 0 1 2 3 5 May–Aug 2016: 1 filed returns Jan–Apr 2017: 2 filed returns May–Aug 2017: 2 filed returns Sep–Dec 2017: 2 filed returns Jan–Apr 2018: 2 filed returns May–Aug 2020: 3 filed returns Sep–Dec 2020: 3 filed returns Jan–Apr 2021: 3 filed returns May–Aug 2021: 3 filed returns Sep–Dec 2021: 4 filed returns Jan–Apr 2022: 2 filed returns May–Aug 2022: 3 filed returns Sep–Dec 2022: 4 filed returns Jan–Apr 2023: 4 filed returns May–Aug 2023: 2 filed returns Sep–Dec 2023: 1 filed returns Jan–Apr 2024: 2 filed returns May–Aug 2024: 1 filed returns Sep–Dec 2024: 3 filed returns Jan–Apr 2025: 4 filed returns May–Aug 2025: 2 filed returns Sep–Dec 2025: 2 filed returns Jan–Apr 2026: 2 filed returns 2017 2018 2021 2022 2023 2024 2025 2026
Filed returns per four-month period Click a column to list its returns.
PeriodRegistrantPolicy areaSubject, as filedOfficials namedLink
Jan–Apr 2026 Pfizer Health Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) 16 On lobbying.ie
Jan–Apr 2026 Pfizer Trade Geopolitical polices in relation to tariffs and Most Favoured Nation (MFN) pricing (Public policy or programme) 4 On lobbying.ie
Sep–Dec 2025 Pfizer Health Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) 4 On lobbying.ie
Sep–Dec 2025 Pfizer Health Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) 19 On lobbying.ie
May–Aug 2025 Pfizer Health Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) 9 On lobbying.ie
May–Aug 2025 Pfizer Trade Raise concern about the impact of potential tariffs and related geo-political issues related to the pharmaceutical industry and pricing of medicines globally (Public policy or programme) 11 On lobbying.ie
Jan–Apr 2025 Pfizer Health Expansion of the National Immunisation Programme to include RSV protection for infants and older adults (Public policy or programme) 6 On lobbying.ie
Jan–Apr 2025 Pfizer Trade Raise concern about the impact of potential tariffs on pharmaceutical manufacturing and supply of medicines to patients globally (Public policy or programme) 11 On lobbying.ie
Jan–Apr 2025 Pfizer EU Affairs EU Pharmaceutical Legislation proposals (Legislation) 7 On lobbying.ie
Jan–Apr 2025 Pfizer Health Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) 7 On lobbying.ie
Sep–Dec 2024 Pfizer Economic Development and Industry Life Science Strategy and Industrial Policy (Public policy or programme) 8 On lobbying.ie
Sep–Dec 2024 Pfizer EU Affairs EU Pharmaceutical Legislation proposals (Legislation) 6 On lobbying.ie
Sep–Dec 2024 Pfizer Health Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) 15 On lobbying.ie
May–Aug 2024 Pfizer EU Affairs EU Pharmaceutical Legislation proposals (Legislation) 14 On lobbying.ie
Jan–Apr 2024 Pfizer EU Affairs EU Pharmaceutical Legislation proposals (Legislation) 9 On lobbying.ie
Jan–Apr 2024 Pfizer Health Ireland's medicine reimbursement system and access to new medicines and vaccines (Matters involving public funds) 14 On lobbying.ie
Sep–Dec 2023 Pfizer Health Ireland's medicine reimbursement system and Budget funding for new medicines (Matters involving public funds) 9 On lobbying.ie
May–Aug 2023 Pfizer EU Affairs EU Pharmaceutical Legislation proposals (Legislation) 5 On lobbying.ie
May–Aug 2023 Pfizer Health Ireland's reimbursement system and funding for new medicines (Public policy or programme) 6 On lobbying.ie
Jan–Apr 2023 Pfizer Economic Development and Industry Pfizer recent 1.2 billion euro investment in Ireland operations creating 400-500 jobs (Public policy or programme) 13 On lobbying.ie
Jan–Apr 2023 Pfizer Health Ireland's pricing and reimbursement system and funding for new medicines (Public policy or programme) 14 On lobbying.ie
Jan–Apr 2023 Pfizer EU Affairs EU Pharmaceutical Legislation (Legislation) 3 On lobbying.ie
Jan–Apr 2023 Pfizer EU Affairs EC HERA contract in relation to Pfizer COVID-19 vaccine (Matters involving public funds) 5 On lobbying.ie
Sep–Dec 2022 Pfizer EU Affairs EC HERA contract in relation to Pfizer COVID-19 vaccine (Matters involving public funds) 5 On lobbying.ie
Sep–Dec 2022 Pfizer Energy and Natural Resources Potential energy shortages (Public policy or programme) 7 On lobbying.ie
Sep–Dec 2022 Pfizer Budgetary matters Budget 2023 (Public policy or programme) 8 On lobbying.ie
Sep–Dec 2022 Pfizer Economic Development and Industry COVID-19 Trips waiver - vaccines and therapeutics (Public policy or programme) 7 On lobbying.ie
May–Aug 2022 Pfizer Budgetary matters Budget 2023 (Public policy or programme) 9 On lobbying.ie
May–Aug 2022 Pfizer Economic Development and Industry COVID-19 Trips waiver - vaccines and therapeutics (Public policy or programme) 17 On lobbying.ie
May–Aug 2022 Pfizer Health COVID-19 vaccination programme (Public policy or programme) 4 On lobbying.ie
Jan–Apr 2022 Pfizer Health Update on Pfizer COVID 19 antiviral treatment and processes in ensuring availability of the treatment in Ireland (Matters involving public funds) 2 On lobbying.ie
Jan–Apr 2022 Pfizer Economic Development and Industry Proposed COVID-19 Trips waiver (Public policy or programme) 12 On lobbying.ie
Sep–Dec 2021 Pfizer Health Agreement on Pricing and Supply of Medicines 2021 - 2025 (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2021 Pfizer Economic Development and Industry Proposed COVID-19 Trips waiver (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2021 Pfizer Health COVID-19 vaccination programme (Public policy or programme) 5 On lobbying.ie
Sep–Dec 2021 Pfizer Health Pfizer has an investigational COVID-19 treatment, a protease inhibitor which subject to clinical trials and regulatory approvals could play a complementary role to vaccination in helping to manage COVID-19 (Matters involving public funds) 5 On lobbying.ie
May–Aug 2021 Pfizer EU Affairs Pfizer has an investigational COVID-19 treatment, a protease inhibitor which subject to clinical trials and regulatory approvals could play a complementary role to vaccination in helping to manage COVID-19 (Public policy or programme) 1 On lobbying.ie
May–Aug 2021 Pfizer Health Supply of Pfizer COVID-19 vaccine including Ireland volumes; expansion of manufacturing capacity to include Grange Castle site and Pfizer colleague vaccination programme (Public policy or programme) 8 On lobbying.ie
May–Aug 2021 Pfizer Economic Development and Industry Globally, debate is underway in relation to a COVID-19 vaccines IP waiver (Public policy or programme) 2 On lobbying.ie
Jan–Apr 2021 Pfizer Economic Development and Industry Highlight the importance of pharmaceutical manufacturing activity being deemed essential activity to ensure the continued operation of Pfizer manufacturing sites wh (Public policy or programme) 2 On lobbying.ie
Jan–Apr 2021 Pfizer EU Affairs Highlight Pfizer concerns re proposed EU vaccine export restrictions and how this could impact Pfizer's ability to manufacture the COVID 19 vaccine and provide supply globally (Public policy or programme) 5 On lobbying.ie
Jan–Apr 2021 Pfizer Health Updates in relation to Pfizer COVID 19 vaccine including global production, Ireland volumes and company colleague vaccination programme (Matters involving public funds) 10 On lobbying.ie
Sep–Dec 2020 Pfizer Economic Development and Industry Highlight the importance of Ireland's pro innovation policies, including corporate tax policy, in ensuring continued investment in Irish operations (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2020 Pfizer Health Highlight Ireland's slowness in reimbursing innovative medicines compared to other European countries and outline factors contributing to this (Public policy or programme) 2 On lobbying.ie
Sep–Dec 2020 Pfizer Health Discussions in relation to Pfizer/BioNtech progress in development of a vaccine for COVID 19 (Public policy or programme) 3 On lobbying.ie
May–Aug 2020 Pfizer Economic Development and Industry Welcomed committment to corporation tax policy and a supportive environment for FDI as outlined in the Programme for Government (Public policy or programme) 28 On lobbying.ie
May–Aug 2020 Pfizer Health Highlighted discussions on extension of industry Supply Agreement and the importance of ensuring expenditure is efficently managed to ensure Irish patients can access innovative medicines; welcomed plans to progress the… (Public policy or programme) 28 On lobbying.ie
May–Aug 2020 Pfizer Health Provided information about Pfizer's research into a COVID-19 vaccine, meeting sought with MoH/DoH. (Public policy or programme) 29 On lobbying.ie
Jan–Apr 2018 Pfizer Taxation Global competition for FDI and life sciences investment continues to intensify and Ireland continues to compete for such investment. Pfizer has extensive operations in Ireland where many of Pfizer's leading and newest… (Public policy or programme) 21 On lobbying.ie
Jan–Apr 2018 Pfizer Health Pfizer is seeking reimbursement for a new treatment for metatastic breast cancer which is reimbursed in the majority of EU countries but not yet in Ireland. Ireland has become one of the slowest countries in Europe to… (Public policy or programme) 4 On lobbying.ie

Policy areas in these returns

Public policy areaFiled returnsShareRelative to the largest
Health 26 45.6%
Economic Development and Industry 14 24.6%
EU Affairs 10 17.5%
Trade 3 5.3%
Budgetary matters 2 3.5%
Energy and Natural Resources 1 1.8%
Taxation 1 1.8%